GSK announces acquisition of RAPT Therapeutics for 2.2 billion dollars
GSK announced the acquisition of U.S.-based RAPT Therapeutics for $2.2 billion on Tuesday. This represents a significant capital deployment for the firm.
Insights:
GSK plc announced on Tuesday, January 20, 2026, that it has reached an agreement to acquire RAPT Therapeutics Inc for $2.2 billion. As reported by Reuters, this acquisition represents a significant capital deployment by the pharmaceutical company to expand its therapeutic portfolio. The transaction scale and its immediate market impact make this a material corporate event for both companies and their respective shareholders.
